Author Archive

RSC Pharmaceutics – Issue 5

13 Dec 2024

We are delighted to share Issue 5 of RSC Pharmaceutics. Read our new open access journal, publishing crucial research on pharmaceutics, which has the potential to drive real change in worldwide health.

“RSC Pharmaceutics will provide a platform for researchers to showcase their best work in this field and contribute to the advancement of Pharmaceutics. I look forward to promoting this journal and its published research to the community.”

Yvonne Perrie, Editor-in-Chief, RSC Pharmaceutics

 

Here are a few of the articles featured in our fifth issue:

 

Graphical abstract: Nano-steps in altered opioid pharmacokinetics: a perspective on potential drug delivery post-bariatric surgery applications

Nano-steps in altered opioid pharmacokinetics: a perspective on potential drug delivery post-bariatric surgery applications

A. E. Avanu, A. M. Ciubotariu, A. M. Ciornei, A. D. Cozmîncă and G. Dodi*

RSC Pharm., 2024,1, 864-878

https://doi.org/10.1039/D4PM00187G

 

 

 

 

 

Graphical abstract: Reconceptualising mucoadhesion for future medicines

Reconceptualising mucoadhesion for future medicines

Michael T. Cook* and David Shorthouse

RSC Pharm., 2024,1, 949-957

https://doi.org/10.1039/D4PM00149D

 

 

 

 

 

Graphical abstract: Increased thermal stability and retained antibacterial properties in a sulbactam and amantadine salt: towards effective antibacterial–antiviral combination therapies

Increased thermal stability and retained antibacterial properties in a sulbactam and amantadine salt: towards effective antibacterial–antiviral combination therapies

Josephine Bicknell, Ivan Bondarenko, Alice Colatrella, Elani J. Cabrera-Vega, Jesus Daniel Loya,  Delbert S. Botes, Jay L. Mellies and Gonzalo Campillo-Alvarado

RSC Pharm., 2024,1, 958-962

https://doi.org/10.1039/D4PM00247D

 

 

 

Graphical abstract: Prodrug nanotherapy demonstrates in vivo anticryptosporidial efficacy in a mouse model of chronic Cryptosporidium infection

Prodrug nanotherapy demonstrates in vivo anticryptosporidial efficacy in a mouse model of chronic Cryptosporidium infection

Amalendu P. Ranjan, Daniel J. Czyzyk, Griselle Martinez-Traverso, Aygul Sadiqova, Margarita Valhondo, Deborah A. Schaefer, Krasimir A. Spasov, William L. Jorgensen, Jamboor K. Vishwanatha, Michael W. Riggs, Alejandro Castellanos-Gonzalez and Karen S. Anderson

RSC Pharm., 2024,1, 963-975

https://doi.org/10.1039/D4PM00093E

 

 

 

Graphical abstract: Structure–activity relationships of DNA nanocarriers based on the amphipathic cell penetrating peptide transportan 10

Structure–activity relationships of DNA nanocarriers based on the amphipathic cell penetrating peptide transportan 10

Lucas Rodrigues de Mello, Tâmisa Seeko Bandeira Honda, Sang Won Han, Valeria Castelletto, Ian William Hamley, Ly Porosk, Ülo Langelcd and Emerson Rodrigo da Silva

RSC Pharm., 2024,1, 976-993

https://doi.org/10.1039/D4PM00065J

 

 

 

 

These articles and our future publications are free to access by anyone.

Start reading now

 RSC Pharmaceutics provides researchers with a platform to publish research in pharmaceutics and advance this field. We are interested in any submission that shares new scientific findings across chemistry, materials science, biomedical sciences, pharmaceutics and drug delivery.

Sign up for email alerts and submit your manuscript.

Comments Off on RSC Pharmaceutics – Issue 5

Subject: Hear from our authors: Shanka Walia and Mohit J. Mehta

20 Sep 2024

RSC Pharmaceutics has published its first articles. To celebrate this, we asked the authors to discuss their work in some more detail.

In this edition, we hear from Shanka Walia and Mohit J. Mehta about their study titled “Recent Progress on Nanosystems for Nucleic Acid Delivery.”

 

“The review provides a comprehensive overview of the use of nanocarriers for the delivery of nucleic acid-based therapeutics. We have discussed the challenges associated with the delivery of nucleic acids, such as their instability, degradation, and inefficient delivery to target cells. The review not only highlights these challenges but also presents a beacon of hope in the form of the potential of lipid-based delivery systems to overcome them. We have discussed various types of lipid-based nanocarriers, including cationic lipids, ionizable lipids, zwitterionic lipids, lipid nanoparticles (LNPs), liposomes, and solid lipid nanoparticles (SLNs). The review also discusses the advantages and disadvantages of each type of nanocarrier. Finally, we have concluded the review by emphasizing the potential of lipid-based nanocarriers to revolutionize the field of nucleic acid therapeutics, inspiring a sense of optimism and anticipation among our readers.

The most exciting aspect of this research is the potential of lipid-based nanocarriers to revolutionize the field of nucleic acid therapeutics. This potential is not just promising, but it’s a game-changer. We have highlighted the many advantages of these nanocarriers, such as their ability to protect nucleic acids from degradation, enhance their cellular uptake, and target them to specific cells and tissues. We have also discussed the recent successes of lipid-based nanocarriers in developing mRNA vaccines for COVID-19. The potential impact of this work is significant. Lipid-based nanocarriers have the potential to enable the development of new and more effective treatments for various diseases, including cancer, genetic disorders, and infectious diseases. Our review provides a valuable overview of the current state of the field. It highlights the challenges that need to be overcome to fully realize the potential of lipid-based nanocarriers.”

 

Want to know more about their work? Read the full paper here!

Graphical abstract: Recent progress on nanosystems for nucleic acid delivery

 

Recent progress on Nanosystems for Nucleic Acid Delivery

Shanka Walia and Mohit J. Mehta

RSC Pharm. 2024, Advance Article, DOI: https://doi.org/10.1039/D4PM00009A

RSC Pharmaceutics provides researchers with a platform to publish research in pharmaceutics and advance this field. We are interested in any submission that shares new scientific findings across chemistry, materials science, biomedical sciences, pharmaceutics and drug delivery.

 

Comments Off on Subject: Hear from our authors: Shanka Walia and Mohit J. Mehta